JPS59176217A - 固形薬剤用粉粒体組成物 - Google Patents
固形薬剤用粉粒体組成物Info
- Publication number
- JPS59176217A JPS59176217A JP5301583A JP5301583A JPS59176217A JP S59176217 A JPS59176217 A JP S59176217A JP 5301583 A JP5301583 A JP 5301583A JP 5301583 A JP5301583 A JP 5301583A JP S59176217 A JPS59176217 A JP S59176217A
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- hardness
- cellulose
- glycolic acid
- powder composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 239000007787 solid Substances 0.000 title claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract 3
- 230000000996 additive effect Effects 0.000 claims abstract 3
- 239000007884 disintegrant Substances 0.000 claims description 18
- 239000001913 cellulose Substances 0.000 claims description 14
- 229920002678 cellulose Polymers 0.000 claims description 14
- 230000005484 gravity Effects 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 9
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical group [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 abstract description 8
- 239000011575 calcium Substances 0.000 abstract description 8
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 abstract description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- 239000007916 tablet composition Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000000704 physical effect Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5301583A JPS59176217A (ja) | 1983-03-28 | 1983-03-28 | 固形薬剤用粉粒体組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5301583A JPS59176217A (ja) | 1983-03-28 | 1983-03-28 | 固形薬剤用粉粒体組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59176217A true JPS59176217A (ja) | 1984-10-05 |
| JPH0526770B2 JPH0526770B2 (https=) | 1993-04-19 |
Family
ID=12931073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5301583A Granted JPS59176217A (ja) | 1983-03-28 | 1983-03-28 | 固形薬剤用粉粒体組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59176217A (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59193815A (ja) * | 1983-04-15 | 1984-11-02 | Daicel Chem Ind Ltd | 錠剤の製法 |
| JPS6048934A (ja) * | 1983-08-29 | 1985-03-16 | Daicel Chem Ind Ltd | 錠剤用粉粒体組成物 |
| JP2002012540A (ja) * | 2000-06-27 | 2002-01-15 | Asahi Kasei Corp | 水易溶性薬物含有錠剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5247914A (en) * | 1975-10-11 | 1977-04-16 | Lilly Industries Ltd | Tablet and its prepation |
| JPS5827984A (ja) * | 1981-08-10 | 1983-02-18 | Kurisutaru Eng Kk | アルミニウム及びその合金のアルカリエツチング液の再生方法 |
| JPS5842722A (ja) * | 1981-09-08 | 1983-03-12 | Kawasaki Steel Corp | 降伏強度或いは０．２％耐力が５５ｋｇｆ／ｍｍ↑２以上の耐硫化物応力腐食割れ性に優れた鋼の製造方法 |
-
1983
- 1983-03-28 JP JP5301583A patent/JPS59176217A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5247914A (en) * | 1975-10-11 | 1977-04-16 | Lilly Industries Ltd | Tablet and its prepation |
| JPS5827984A (ja) * | 1981-08-10 | 1983-02-18 | Kurisutaru Eng Kk | アルミニウム及びその合金のアルカリエツチング液の再生方法 |
| JPS5842722A (ja) * | 1981-09-08 | 1983-03-12 | Kawasaki Steel Corp | 降伏強度或いは０．２％耐力が５５ｋｇｆ／ｍｍ↑２以上の耐硫化物応力腐食割れ性に優れた鋼の製造方法 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59193815A (ja) * | 1983-04-15 | 1984-11-02 | Daicel Chem Ind Ltd | 錠剤の製法 |
| JPS6048934A (ja) * | 1983-08-29 | 1985-03-16 | Daicel Chem Ind Ltd | 錠剤用粉粒体組成物 |
| JP2002012540A (ja) * | 2000-06-27 | 2002-01-15 | Asahi Kasei Corp | 水易溶性薬物含有錠剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0526770B2 (https=) | 1993-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5681156B2 (ja) | リン酸結合性ポリマー製剤 | |
| RU2501561C1 (ru) | Антацидная и слабительная таблетка | |
| HU228149B1 (en) | Film coated tablet of paracetamol and domperidone | |
| KR20130016386A (ko) | 구강내 붕괴 정제 | |
| TW446562B (en) | Pharmaceutical composition for increasing calcium uptake | |
| KR101677775B1 (ko) | 붕괴성 및 용출성에 우수한 내복용 정제 | |
| JP4562797B1 (ja) | 沈降炭酸カルシウムを有効成分とする口腔内崩壊錠 | |
| JPS59176217A (ja) | 固形薬剤用粉粒体組成物 | |
| KR101813065B1 (ko) | 알긴산 및/또는 알긴산염을 포함하는 고형 제제 | |
| JP3884056B1 (ja) | 口腔内速崩錠の製造方法 | |
| JPH0526762B2 (https=) | ||
| JP6341196B2 (ja) | 固形製剤 | |
| JPS59155310A (ja) | 崩壊性の改良された固型薬剤の製造方法 | |
| JP3967767B1 (ja) | 口腔内速崩錠の製造方法 | |
| IE51157B1 (en) | Sustained release theophylline tablet having reduced bulk | |
| Danki | Effect of binding agents and disintegrants on the dissolution rate of lornoxicam from compressed tablets | |
| JP2524497B2 (ja) | 持続性固形剤 | |
| Eziuzo et al. | Formulation and Evaluation of Floating Matrix Tablets of Ciprofloxacin Using Sida acuta Gum. Against Some Pathogenic Bacteria | |
| Sahoo et al. | FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLETS OF GRANISETRON HYDROCHLORIDE USING PLANTAGO OVATE AS NATURAL SUPERDISINTEGRANTS. | |
| JPS60152424A (ja) | 固形製剤 | |
| JP2021506750A (ja) | アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法 | |
| Sanam et al. | Design and In-Vitro evaluation of Indapamide Sustained Release Tablet using Methocel K15 Mcr and Methocel K100m Lvcr | |
| Lestari et al. | THE EFFECT OF REPEATED COMPRESSION AND CONCENTRATION OF MALTODEXTRIN AS A BINDER ON THE QUALITY OF CALCIUM LACTATE TABLETS | |
| JPH0465813B2 (https=) | ||
| Ugoeze et al. | EVALUATION OF A MODIFIED BIOMATERIAL OF TYMPANOTONUS FUSCATA SHELL POWDER II: FORMULATION OF PYRIMETHAMINE AND PYRIDOXINE HYDROCHLORIDE TABLETS |